Sinaptica seeks immediate connections to clinical trial sites, foundations, and funders to launch their FDA-negotiated pivotal trial with an available device prototype, targeting 2029 market entry for a therapy that achieved statistically significant slowing across all three domains (cognitive, functional, behavioral) in Alzheimer's patients with zero side effects and $20,000+ annual reimbursement codes already secured.
Treatment achieved statistically significant slowing of cognitive, functional, and behavioral decline across all three domains in Alzheimer's patients, an unusual outcome in Alzheimer's research
Therapy has zero side effects, can be combined with any drug, and delivers efficacy that drugs cannot achieve in Alzheimer's treatment per CEO assessment
Sinaptica's pivotal trial is ready to launch immediately with device prototype available and FDA trial design fully negotiated, targeting 2029 market entry
Are you ready to tell YOUR story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world’s biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is available to StartUp Health Members. If you’re mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit.
👉 Learn more and join today.
The Year-End Moves No One’s Watching
Markets don’t wait — and year-end waits even less.
In the final stretch, money rotates, funds window-dress, tax-loss selling meets bottom-fishing, and “Santa Rally” chatter turns into real tape. Most people notice after the move.
Elite Trade Club is your morning shortcut: a curated selection of the setups that still matter this year — the headlines that move stocks, catalysts on deck, and where smart money is positioning before New Year’s. One read. Five minutes. Actionable clarity.
If you want to start 2026 from a stronger spot, finish 2025 prepared. Join 200K+ traders who open our premarket briefing, place their plan, and let the open come to them.
By joining, you’ll receive Elite Trade Club emails and select partner insights. See Privacy Policy.
